Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer

Eli Lilly and Company44 enrolled

Overview

The study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

AbemaciclibDRUG

Administered orally

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participant must have metastatic prostate cancer for which castration (medical or surgical) is no longer effective (castration-resistant). * Participant must have disease spread to soft tissue that is measurable. * Participant must have documented evidence of progressive disease by PSA test or imaging. * Participant must have previously received at least one of the following treatment: abiraterone acetate, apalutamide, darolutamide or enzalutamide. * Participant must have previously received chemotherapy with docetaxel and cabazitaxel. * Participant must be willing and amenable to undergo a biopsy of tumor tissue (or able to provide adequate archived tumor tissue sample) and to provide blood for research. * Participant must have good physical functioning ability and adequate organ function. Exclusion Criteria: * Participant must not have received more than 3 therapy regimens for metastatic castration-resistant prostate cancer (NOTE: GnRHa, first-generation antiandrogens (flutamide, nilutamide, or bicalutamide), diethylstilbestrol (DES) (or other estrogens), corticosteroids, ketoconazole, and bone loss-prevention will not count as systemic therapy regimens. * Participants must not have previously received abemaciclib or any cyclin-dependent kinase (CDK)4 and/or CDK6 inhibitors. * Participants must not have serious and/or uncontrolled preexisting medical condition(s) including but not limited to severe renal impairment, severe hepatic impairment, interstitial lung disease (ILD)/pneumonitis, severe dyspnea at rest or requiring oxygen therapy or other serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study. * Participants must not have, or suspected to have, brain metastasis. * Participants must not have untreated spinal cord compression, evidence of spinal metastases with risk of spinal compression or structurally unstable bone lesions suggesting impending fracture.

Locations (14)

University of Utah - Huntsman Cancer Institute

Salt Lake City, Utah, United States

Seattle Cancer Care Alliance

Seattle, Washington, United States

Centre Leon Berard

Lyon, France

Outcomes

Primary Outcomes

Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR])

ORR is defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) in soft tissue per response evaluation criteria in solid tumors (RECIST) version 1.1 and do not have concurrent bone progression per Prostate Cancer Clinical Trials Working Group 3 (PCWG3), as assessed by the investigator. ORR = (participants with confirmed CR and no bone progression) + (participants with confirmed PR and no bone progression) x 100 / all treated participants.

Time frame: From Date of First Dose until Objective Progression (Up To 12.8 Months)

Secondary Outcomes

Radiographic Progression-Free Survival (rPFS)

The rPFS time is measured from the date of first dose to the earliest date of investigator-assessed radiographic progression per RECIST 1.1 for soft tissue and PCWG3 criteria for bone, or death from any cause, whichever occurred first. Participants who have neither progressed nor died will be censored at the day of their last radiographic tumor assessment (if available) or date of first dose if no post initiation (i.e., postbaseline) radiographic assessment is available.

Time frame: From Date of First Dose until Objective Progression or Death from Any Cause (Up To 12.8 Months)

Overall Survival (OS)

OS time is measured from the date of first dose to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.

Time frame: From Date of First Dose until Date of Death from Any Cause (Up To 28 Months)

Duration of Response (DoR)

DoR is measured only for confirmed responders (participants with a confirmed soft tissue best overall response of CR or PR per RECIST 1.1 no concurrent bone progression per PCWG3). It is measured from the date of first evidence of soft tissue CR or PR to the earliest date of investigator-assessed radiographic progression or death from any cause, whichever is earlier.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Institut Paoli-Calmettes

Marseille, France

Hopital Europeen Georges Pompidou

Paris, France

Institut Claudius Regaud

Toulouse, France

Gustave Roussy

Villejuif, France

Institut Catala d'Oncologia

L'Hospitalet de Llobregat, Barcelona, Spain

Corporacion Sanitaria Parc Tauli

Sabadell, Barcelona, Spain

Hospital de la Santa Creu i Sant Pau

Barcelona, Spain

...and 4 more locations

Time frame: CR or PR to Disease Progression or Death Due to Any Cause (Up to 12 Months)

Percentage of Participants Achieving CR, PR or Stable Disease (SD) (Disease Control Rate [DCR])

The DCR is defined as the percentage of participants with confirmed soft tissue best overall response of CR, PR, or stable disease (SD) per RECIST 1.1, and do not have concurrent bone disease progression per PCWG3.

Time frame: From Date of First Dose until Measured Progressive Disease or Death Due to Any Cause (Up To 12.8 Months)

Time to Prostate-Specific Antigen (PSA) Progression

Time to PSA progression is defined as the time from the date of treatment initiation to the date of first observation of PSA progression. The PSA progression is defined as a greater than or equal to (\>=) 25 percentage (%) increase and an absolute increase of \>=2 nanogram/milliliter (ng/mL) above the nadir (or baseline value if baseline is the smallest on study), which is confirmed by a second value obtained 3 or more weeks later.

Time frame: From Date of First Dose until Confirmed PSA Progression (Up To 12.8 Months)

Percentage of Participants Who Achieved Prostate-Specific Antigen (PSA) Response (PSA Response Rate)

The PSA response rate is defined as the percentage of participants with a reduction in PSA level ≥50% from baseline, confirmed with a second assessment conducted at least 3 weeks later.

Time frame: From Date of First Dose until Confirmed PSA Progression (Up To 12.8 Months)

Time to Symptomatic Progression

Time to symptomatic progression is defined as the time from first dose to any of the following (whichever occurred earlier): 1) symptomatic skeletal event, defined as symptomatic fracture, surgery, or radiation to bone, or spinal cord compression; 2) pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anticancer therapy; and 3) development of clinically significant symptoms due to locoregional tumor progression requiring surgical intervention or radiation therapy. For participants who were not known to have symptomatic progression at the time of data analysis, data were censored on the last date at which no symptomatic progression was indicated.

Time frame: From Date of First Dose until Symptomatic Progression (Up to 12.8 Months)

Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib

PK: Cmax,ss of abemaciclib is reported. The cycle length was 28 days.

Time frame: Cycle (C) 1 Day (D) 1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose

PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib

PK: Cmin,ss of abemaciclib is reported.

Time frame: C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose

PK: Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib Metabolites (Total Active Species)

PK: Cmax,ss of abemaciclib metabolites (Total Active Species) is reported.

Time frame: C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose

PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib Metabolites (Total Active Species)

PK: Cmin,ss of abemaciclib metabolites (Total Active Species) is reported.

Time frame: C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose

Percentage of Participants With Expression of Ki-67 Proliferation Marker by Immunohistochemistry (IHC)

Percentage of participants with expression of Ki-67 proliferation marker at baseline by immunohistochemistry. Baseline expression of the Ki-67 proliferation marker was evaluated by IHC utilizing a 20% or higher score to define high Ki-67 expression. The percentage of Ki-67 positive cells was defined by the number of non-apoptotic tumor cells with unequivocal brown nuclear staining (intensities ≥1 using a 0-3 scale) over the total number of non-apoptotic tumor cells. Unit of Measure is percentage of participants with low or high baseline Ki-67 expression.

Time frame: Baseline